Genomica Completes $13.6M Private Financing

BOULDER, COLO. (March 1) BW HEALTHWIRE -March 1, 1999--Genomica Corp., a leading pharmacogenomics software company developing tools to facilitate gene discovery and drug development, announced today the completion of a $13.6 million private placement of Series B Convertible Preferred Stock.

Managed by Punk, Ziegel & Company, the private placement included such new investment groups as The Kaufmann Fund and Anvers L.P., as well as previous investors, Falcon Technology Partners, INVESCO Global Heath Sciences Fund, ARCH Venture Partners, Boulder Ventures and others.

Proceeds of this offering will be used for marketing the Company's products as well as additional product development. "We are pleased with the experience the new investors bring to the Company in addition to that of our current investors. Genomica is positioned to provide the single best pharmacogenomics solution to the rapidly expanding pharmaceutical and bioinformatics markets," said Tom Marr, Ph.D., Genomica's president and chief scientist.

"The gold rush is on to find the function of genes. Genomica provides the software picks and shovels that will help geneticists and functional genomicists find the gold in the genome. Users I've spoken to praise the product for its industrial strength quality and ease of use. It appears that Genomica has the chance to be 'the Bloomberg(TM)' or 'the Microsoft Excel(TM)' of genomics," said Skip Klein, CFA, Healthcare Analyst of The Kaufmann Fund.

Genomica Corp. is a privately held pharmacogenomics software company headquartered in Boulder. The company's tools combine clinical, epidemiology, genetic, molecular biology, and biochemistry applications into a single software package that enables scientists to accelerate genetic discoveries, disease gene cloning and gene functional analysis.

The Genomica software supports a range of research activities and provides data that can be accessed and utilized by pharmaceutical and biotechnology companies. The company was established in 1996 by Thomas G. Marr, Ph.D., president and chief scientist of Genomica, to commercialize the tools he and his team developed at Cold Spring Harbor Laboratory in New York.

-0- pw/sf* dl/sf

CONTACT: Genomica Corp.

          Dr. Thomas G. Marr, 303/402-9800 

or

          Russell-Welch 

Les Stickles, 650/312-0700

KEYWORD: COLORADO NEW YORK
INDUSTRY KEYWORD: MEDICINE BIOTECHNOLOGY PHARMACEUTICAL
COMPUTERS/ELECTRONICS COMED Today's News On The Net - Business Wire's
full file on the Internet

with Hyperlinks to your home page.

                      URL: http://www.businesswire.com